PhotoPharmics develops Celeste®, a specialized phototherapy device that utilizes specific wavelengths of light to regulate circadian rhythms and alleviate both motor and non-motor symptoms of Parkinson's disease. This non-invasive treatment addresses the retinal deterioration and circadian dysregulation associated with neurodegenerative disorders, improving quality of life for patients.
Funding
$16.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson's disease (PD) affects millions worldwide, leading to motor and non-motor symptoms that significantly reduce quality of life. Current treatments, largely pharmacological, often fail to address the full spectrum of symptoms, and there is a growing need for non-invasive, non-pharmacological therapies.
Solution
PhotoPharmics offers Celeste®, a specialized phototherapy device designed to address both motor and non-motor symptoms of Parkinson's disease. Celeste® delivers specific wavelengths of light to the eye, stimulating retinal neurons that signal to brain areas responsible for sleep, wakefulness, mood, and energy regulation. This non-invasive approach aims to restore retinal signaling, complementing existing medical treatments without requiring changes to medication regimens. The therapy is administered passively during daily activities like watching TV or reading, offering a convenient and accessible treatment option.
Target Audience
The primary target audience includes individuals diagnosed with Parkinson's disease seeking non-invasive, non-pharmacological treatments to improve motor and non-motor symptoms, as well as neurologists and movement disorder specialists looking for complementary therapies.
Features
- Non-invasive phototherapy delivered through a specialized light device
- Specific wavelengths of light target retinal neurons to stimulate brain function
- Designed to address both motor and non-motor symptoms of Parkinson's disease
- Passive administration during daily activities, complementing existing treatments
- At-home, telemedicine-based format enhances accessibility and convenience